AskBio in the News
Press Releases
As one of the leading gene therapy companies, we are continuously advancing AAV therapeutics, discovering new technology, forging new research collaborations, and adding amazing talent to our team.
AskBio Announces Publication of Complete Results of Phase 1b Trial of AB-1005 Gene Therapy in Participants with Parkinson’s Disease in Movement Disorders
AB-1005 was well tolerated with no attributed serious adverse events in participants with mild or…
AskBio Presents Complete Results of Phase 1 Trial of AB-1002 Gene Therapy in Participants with Congestive Heart Failure at European Society of Cardiology Heart Failure Meeting
First-in-human trial of AB-1002 designed to evaluate safety and preliminary efficacy in participants with New York…
AskBio Announces 15 Presentations at American Society of Gene and Cell Therapy 28th Annual Meeting
Three oral and 12 poster presentations demonstrate breadth and progress of AskBio’s gene therapy research…
AskBio Elects Dr. Laura Sepp-Lorenzino Independent Member of Board of Directors
Dr. Sepp-Lorenzino brings to AskBio over 30 years of executive, academic, and Board experience Other…
AskBio Advances Gene Therapy Clinical Trial for Limb-Girdle Muscular Dystrophy Type 2I/R9 with Dosing of First Participant in Second Cohort
Data Safety Monitoring Board (DSMB) recommendation to initiate second cohort follows review of Phase 1/Phase…
AskBio Receives FDA Regenerative Medicine Advanced Therapy designation for Parkinson’s disease investigational gene therapy
Not intended for UK Media Regenerative Medicine Advanced Therapy (RMAT) designation follows Phase Ib 36-month…
First Participant Randomized in Europe in AskBio Phase 2 Gene Therapy Trial for Congestive Heart Failure
AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and…
First participants randomized in AskBio Phase II gene therapy trial for Parkinson’s disease
Enrollment ongoing in the United States for REGENERATE-PD clinical trial of AB-1005 (also known as…
AskBio Receives FDA Rare Pediatric Disease and Orphan-Drug Designations for AB-1003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9
First patient dosed in Phase 1/Phase 2 LION-CS101 trial of AB-1003 in August 2023, with…
AskBio Announces 11 Presentations at the European Society of Gene and Cell Therapy 31st Annual Meeting 2024
Two oral presentations and nine poster presentations will highlight exciting progress in AskBio’s clinical and…
AskBio to collaborate with Belief BioMed to explore the potential of new gene therapies
AskBio and Belief BioMed will work together to advance potential gene therapies in diseases with…
AskBio receives FDA Fast Track and MHRA Innovation Passport designations for AB-1005 investigational GDNF gene therapy for Parkinson’s disease
AB-1005 (formerly known as AAV2-GDNF) is being studied for the treatment of patients with moderate…
AskBio Initiates Recruitment to its Phase 2 Parkinson’s Disease Trial
REGENERATE-PD, which is now enrolling, will study AB-1005, an adeno-associated virus 2 (AAV2) glial cell…
AskBio Announces Nine Presentations at American Society of Gene and Cell Therapy 27th Annual Meeting 2024
Four oral and five poster presentations demonstrate breadth and progress of AskBio’s gene therapy research,…
AskBio receives FDA Fast Track Designation for AB-1002 investigational gene therapy program in congestive heart failure
AB-1002 is being studied for the treatment of adults with non-ischemic cardiomyopathy and New York…
AskBio presents 18-month Phase Ib trial results of AB-1005 gene therapy for patients with Parkinson’s disease
AB-1005 (also known as AAV2-GDNF), an investigational gene therapy for the treatment of Parkinson’s disease,…
AskBio Names Mansuo Shannon Chief Scientific Officer
Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company…
First patient randomized in AskBio Phase II gene therapy trial for congestive heart failure
Not intended for UK Media AB-1002 is an investigational gene therapy for the treatment of…
AskBio Announces Initiation of Phase 2 GenePHIT Trial in Congestive Heart Failure (CHF)
GenePHIT, which is now enrolling, will study AB-1002 in adults with NYHA Class III Heart…
AskBio Phase Ib trial of AB-1005 gene therapy in patients with Parkinson’s disease meets primary endpoint
AB-1005 (AAV2-GDNF), an investigational gene therapy for the treatment of Parkinson’s disease, was well tolerated…
AskBio Announces First Patient Randomized in Phase 1 Trial of AB-1005 (AAV2-GDNF) Gene Therapy for Multiple System Atrophy-Parkinsonian Type (MSA-P)
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels…
AskBio Presents Preliminary Data from Phase 1 Trial of Gene Therapy for Congestive Heart Failure (CHF) at the 2023 American Heart Association Scientific Sessions
First-in-human trial of AB-1002 designed to establish safety and preliminary efficacy in patients with NYHA Class…
AskBio Contribution to Advancing Gene Therapy Highlighted at ESGCT 30th Congress
Updated AskBio Leadership Structure Reflects Strategic Focus
Newly created Chief Business Officer, Chief Strategy Officer, Chief Product Supply Officer, and Head of…
AskBio Announces First Patient Dosed in Phase 1 / Phase 2 Trial of AB-1003 Gene Therapy for Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
Gene therapy developed to restore FKRP enzyme activity, primarily inside muscle cells, for the treatment…
AskBio Announces 11 Presentations at the American Society of Gene and Cell Therapy 26th Annual Meeting in 2023
Four oral presentations and seven poster presentations will share insights into AskBio’s adeno-associated virus research, development and…
AskBio to Present Phase 1b Results Investigating AB-1005 (formerly AAV2-GDNF) as Treatment for Parkinson’s Disease at AD/PDTM 2023 International Conference on Alzheimer’s and Parkinson’s Diseases
—Preliminary data suggest that gene therapy via neurosurgical administration is generally safe, well tolerated and…
AskBio Announces Gustavo Pesquin as New CEO
Research Triangle Park, N.C.– March 9, 2023 – Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently…
AskBio Receives European Commission Orphan Drug Designation through its EU-Based subsidiary BrainVectis for AB-1003, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy (LGMD)
— LGMD is a Rare Form of Muscular Dystrophy with No Approved Therapy — Research…
AskBio Co-Founder R. Jude Samulski and Team of AskBio Scientists Author Paper Published in Prestigious Journal
— Leading research journal, Molecular Therapy, published a manuscript that explores the improvement and expansive use…
AskBio Announces Strategic Collaboration with ReCode Therapeutics to Explore Single Vector Gene Editing Platform
Research Triangle Park, N.C. (January 9, 2023) – Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned and independently…
Recombinant Adeno-Associated Virus (rAAV) Technology
Pioneered by AskBio’s Dr. Jude Samulski is Key Component
of All FDA Approved AAV Gene Therapeutics
Research Triangle Park, N.C. (December X, 2022) – Asklepios BioPharmaceutical, Inc. (AskBio), a wholly-owned and independently-operated subsidiary…
AskBio Vice President and Neurobiology Sector Lead Nathalie Cartier Honored with Ann B. Moser Award
Research Triangle Park, N.C.– November 17, 2022 – Asklepios BioPharmaceutical, Inc. (AskBio), a wholly-owned and independently-operated…
AskBio CEO and Co-Founder Sheila Mikhail Named One of the Fiercest Women in Life Sciences 2022
Research Triangle Park, N.C.– November 14, 2022 – Asklepios BioPharmaceutical, Inc. (AskBio), a wholly-owned and independently-operated…
AskBio Co-Founder Jude Samulski Receives Inaugural European Society of Gene and Cell Therapy Founders Award
— Award recognizes 40th anniversary of groundbreaking first cloning of AAV plasmid — Research Triangle…
AskBio Contribution to Advancing Gene Therapy Highlighted at ESGCT 29th Congress
— Company presence includes 2 oral and 12 poster presentations — Research Triangle Park, N.C.–…
AskBio Named One of Triangle’s Best Places to Work
Triangle Business Journal Selection Based on Employee-Provided Rankings in Six Categories Research Triangle Park, NC…
BrainVectis, a subsidiary of AskBio, receives clearance to conduct Phase I/II clinical trial in France for its novel gene therapy for early-stage Huntington’s Disease
National Agency for Safety of Medicines and Health Products (ANSM) and French Ethics Committee approve…
AskBio Bolsters its Global Leadership Team with Two New Executives
Doug Schantz joins as Senior Vice President of Clinical Operations and Phil McNamara to serve as…
AskBio CEO and Co-Founder Sheila Mikhail receives 2022 Entrepreneurial Award from University of Chicago Booth School of Business
Prestigious recognition for outstanding professional achievement in the formation of a successful enterprise awarded to…
AskBio President of Therapeutics Dr. Katherine High receives Award from American Society of Gene and Cell Therapy
Jerry Mendell Award recognizes Dr. High for her outstanding work to bring cell and gene therapies…
AskBio to Present 11 Abstracts at Upcoming American Society of Gene and Cell Therapy’s 25th Annual Meeting
Presentations convey essential technological and scientific knowledge regarding AAV gene therapy and advancements across key disease…
AskBio and Touchlight Restructure Joint Venture
AskBio Names Philip Dana Chief Human Resources Officer
AskBio Receives FDA Fast Track Designation for LION-101, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9)
AskBio Announces IND for LION-101, a Novel Investigational AAV Gene Therapy for the Treatment of Limb-Girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9), Cleared to Proceed by U.S. FDA
AskBio Named 2021 Life Sciences Awards Company of the Year Winner by Triangle Business Journal
AskBio Announces Presentations at Upcoming American Society of Gene and Cell Therapy’s 24th Annual Meeting
Selecta Biosciences and AskBio Announce Updates to Methylmalonic Acidemia (MMA-101) Program
Selecta and AskBio Initiate First-in-Human Dose-Escalation Study to Evaluate ImmTOR in Gene Therapy
AskBio Adds CNS Gene Therapy Programs in Parkinson’s Disease and Multiple System Atrophy
Gene Therapy Leader Katherine High Joins AskBio as President, Therapeutics
AskBio Applauds Commencement of Pfizer’s Pivotal Trial for Duchenne Muscular Dystrophy
AskBio Welcomes Brain Neurotherapy Bio to Expand Clinical Pipeline for Neurodegenerative Diseases
AskBio CSO Jude Samulski Named 2020 Business Person of the Year by Triangle Business Journal
AskBio and Selecta Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic Acidemia
Bayer Acquires AskBio to Broaden Innovation Base in Cell and Gene Therapy
Selecta and AskBio Receive FDA Rare Pediatric Disease Designation for Methylmalonic Acidemia Gene Therapy
Kellie Sears Named AskBio Chief Human Resources Officer
AskBio Awarded £2m Scottish Enterprise R&D Grant to Help Reduce Barriers to Mainstream Gene Therapy
AskBio CSO Jude Samulski Receives 2020 Life Sciences Award from the Triangle Business Journal
AskBio Named to Inc. 5000 List of Fastest-Growing Private Companies
AskBio Appoints Michael Kranda as SVP Therapeutic Practice Leader for Its Growing CNS Portfolio
AskBio CSO Jude Samulski Named One of the Most Inspiring Leaders in Life Sciences by PharmaVOICE Magazine
Libbie Mansell Joins AskBio as SVP Regulatory Affairs
AAV Gene Therapy Pioneer Jude Samulski Develops Proprietary Regulated Gene Editing System
AskBio Appoints Tim Trost as Chief Financial Officer
AskBio Acquires BrainVectis to Expand its Clinical Pipeline for Neurodegenerative Diseases
Don Haut, PhD, Joins AskBio as Chief Business Officer
AskBio Enters Research Collaboration and Licensing Agreement with University of North Carolina (UNC) for Angelman Syndrome
Tim Kelly Joins AskBio as President of Manufacturing to Lead AAV Vector Production for Gene Therapy
CYTOO and AskBio Enter into Research Agreement to Screen Gene Therapy Candidates for Rare Muscle Disorder
AskBio Appoints Anna Tretiakova, PhD, as Senior Vice President of Product Development
AskBio Launches AskFirst™ Patient Advocacy Program to Educate and Support Participants in Gene Therapy Clinical Trials
AskBio To Present At The 38th Annual J.P. Morgan Healthcare Conference
AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease
AskBio Receives “Best Venture Funding” Award from Southeast BIO
SQZ Biotech and AskBio Announce Research Collaboration to Create Immune Tolerization Products for AAV Gene Therapies
Sheila Mikhail, AskBio CEO and Cofounder, Named Springboard Enterprises’ 2019 Northstar Honoree
Editas Medicine and AskBio Enter Strategic Research Collaboration to Explore In Vivo Delivery of Genome Editing Medicines to Treat Neurological Diseases
AskBio Acquires Assets from RoverMed BioSciences, Adds Nanotechnology Precision to Delivery of AAV Gene Therapeutics
Viralgen Receives cGMP Certification from European Medicines Agency
AskBio Applauds Pfizer’s Continuing Investments in Gene Therapy
AskBio Acquires Synpromics Ltd. and Expands its Gene Therapy Technology Portfolio
Selecta Biosciences Combines ImmTOR™ Platform with AskBio’s IndustryLeading Gene Therapy Platform in Strategic Partnership
Statement: Pfizer Phase 1b Clinical Trial Results
Newly Approved Spinal Muscular Atrophy Gene Therapy, Zolgensma®, Validates AskBio Gene Therapy Platform
AskBio Partners with TPG and Vida Ventures
First Patient Dosed with Gene Therapy in Phase 1/2 Study of ACTUS-101 in Patients with Pompe Disease
Asklepios BioPharmaceutical, Inc. Launches New Portfolio Company – Actus Therapeutics, Inc.
AskBio and Columbus Venture Partners Launch Gene Therapy Company Viralgen
NanoCor Announces New Data on Congestive Heart Failure Gene Therapy
Pfizer Aims To Become Industry Leader In Gene Therapy With Acquisition Of Bamboo Therapeutics, Inc.
AskBio and AveXis Finalize License
CHAPEL HILL, N.C.– June 17, 2015 –Asklepios BioPharmaceutical, Inc. (AskBio) and AveXis, Inc. (AveXis) have…
Baxter to Acquire Chatham Therapeutics
Asklepios BioPharmaceutical Enters Into A Patent License Agreement With Pfizer
Medtronic Makes Equity Investment in NanoCor Therapeutics, Inc.
Media inquiries
We take pride in our relationships with media representatives. Our scientific experts are always available if needed for interviews and their insights.
Media contact:
Philip McNamara, Vice President, Communications
